Literature DB >> 27177902

TUSC3 suppresses glioblastoma development by inhibiting Akt signaling.

Zhenfeng Jiang1, Mian Guo2, Xiangtong Zhang1, Lifen Yao3, Jia Shen4, Guizhen Ma5, Li Liu1, Liwei Zhao1, Chuncheng Xie1, Hongsheng Liang1, Haiyang Wang1, Minwei Zhu1, Li Hu1, Yuanyuan Song1, Hong Shen1, Zhiguo Lin6.   

Abstract

Glioblastoma multiform is one of the most common and most aggressive brain tumors in humans. The molecular and cellular mechanisms responsible for the onset and progression of GBM are elusive and controversial. The function of tumor suppressor candidate 3 (TUSC3) has not been previously characterized in GBM. TUSC3 was originally identified as part of an enzyme complex involved in N-glycosylation of proteins, but was recently implicated as a potential tumor suppressor gene in a variety of cancer types. In this study, we demonstrated that the expression levels of TUSC3 were downregulated in both GBM tissues and cells, and also found that overexpression of TUSC3 inhibits GBM cell proliferation and invasion. In addition, the effects of increased levels of methylation on the TUSC3 promoter were responsible for decreased expression of TUSC3 in GBM. Finally, we determined that TUSC3 regulates proliferation and invasion of GBM cells by inhibiting the activity of the Akt signaling pathway.

Entities:  

Keywords:  Akt signaling; Glioblastoma; Methylation; TUSC3

Mesh:

Substances:

Year:  2016        PMID: 27177902     DOI: 10.1007/s13277-016-5072-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  50 in total

1.  The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway.

Authors:  Min Fang; Zhirong Shen; Song Huang; Liping Zhao; She Chen; Tak W Mak; Xiaodong Wang
Journal:  Cell       Date:  2010-11-11       Impact factor: 41.582

2.  microRNA-21 mediates epithelial-mesenchymal transition of human hepatocytes via PTEN/Akt pathway.

Authors:  Zhenyu Liu; Jingjie Wang; Chuanyong Guo; Xiaoming Fan
Journal:  Biomed Pharmacother       Date:  2014-11-06       Impact factor: 6.529

3.  MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma.

Authors:  Fei Wang; Weizhong Xiao; Jiyong Sun; Donghua Han; Youhou Zhu
Journal:  Tumour Biol       Date:  2014-05-28

Review 4.  An evolving view of the eukaryotic oligosaccharyltransferase.

Authors:  Daniel J Kelleher; Reid Gilmore
Journal:  Glycobiology       Date:  2005-11-29       Impact factor: 4.313

Review 5.  Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours.

Authors:  Akira Kobata; Junko Amano
Journal:  Immunol Cell Biol       Date:  2005-08       Impact factor: 5.126

6.  Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer.

Authors:  Murali D Bashyam; Ryan Bair; Young H Kim; Pei Wang; Tina Hernandez-Boussard; Collins A Karikari; Robert Tibshirani; Anirban Maitra; Jonathan R Pollack
Journal:  Neoplasia       Date:  2005-06       Impact factor: 5.715

7.  A novel deletion mutation in the TUSC3 gene in a consanguineous Pakistani family with autosomal recessive nonsyndromic intellectual disability.

Authors:  Muzammil Ahmad Khan; Muhammad Arshad Rafiq; Abdul Noor; Nadir Ali; Ghazanfar Ali; John B Vincent; Muhammad Ansar
Journal:  BMC Med Genet       Date:  2011-04-22       Impact factor: 2.103

8.  miR-93 promotes cell proliferation in gliomas through activation of PI3K/Akt signaling pathway.

Authors:  Lili Jiang; Chanjuan Wang; Fangyong Lei; Longjuan Zhang; Xin Zhang; Aibin Liu; Geyan Wu; Jinrong Zhu; Libing Song
Journal:  Oncotarget       Date:  2015-04-10

9.  Functional characterization of Ost3p. Loss of the 34-kD subunit of the Saccharomyces cerevisiae oligosaccharyltransferase results in biased underglycosylation of acceptor substrates.

Authors:  D Karaoglu; D J Kelleher; R Gilmore
Journal:  J Cell Biol       Date:  1995-08       Impact factor: 10.539

10.  TUSC3 loss alters the ER stress response and accelerates prostate cancer growth in vivo.

Authors:  Peter Horak; Erwin Tomasich; Petr Vaňhara; Kateřina Kratochvílová; Mariam Anees; Maximilian Marhold; Christof E Lemberger; Marion Gerschpacher; Reinhard Horvat; Maria Sibilia; Dietmar Pils; Michael Krainer
Journal:  Sci Rep       Date:  2014-01-17       Impact factor: 4.379

View more
  12 in total

Review 1.  TUSC3: functional duality of a cancer gene.

Authors:  Kateřina Vašíčková; Peter Horak; Petr Vaňhara
Journal:  Cell Mol Life Sci       Date:  2017-09-19       Impact factor: 9.261

2.  UHRF1-KAT7-mediated regulation of TUSC3 expression via histone methylation/acetylation is critical for the proliferation of colon cancer cells.

Authors:  Kenzui Taniue; Tomoatsu Hayashi; Yuki Kamoshida; Akiko Kurimoto; Yasuko Takeda; Lumi Negishi; Kei Iwasaki; Yoshifumi Kawamura; Naoki Goshima; Tetsu Akiyama
Journal:  Oncogene       Date:  2019-10-03       Impact factor: 9.867

3.  ZFPM2-AS1 transcriptionally mediated by STAT1 regulates thyroid cancer cell growth, migration and invasion via miR-515-5p/TUSC3.

Authors:  Ruizhen Ren; Yuanna Du; Xing Niu; Rukun Zang
Journal:  J Cancer       Date:  2021-04-17       Impact factor: 4.207

4.  Comprehensive analysis of the long noncoding RNA HOXA11-AS gene interaction regulatory network in NSCLC cells.

Authors:  Yu Zhang; Rong-Quan He; Gang Chen; Ting-Qing Gan; Yi-Wu Dang; Xiu-Ling Zhang; Xiao Wang; Su-Ning Huang; Wen-Ting Huang; Meng-Tong Jiang; Xiao-Ning Gan; You Xie; Ping Li; Dian-Zhong Luo
Journal:  Cancer Cell Int       Date:  2016-12-01       Impact factor: 5.722

Review 5.  Regulation of EMT in Colorectal Cancer: A Culprit in Metastasis.

Authors:  Trung Vu; Pran K Datta
Journal:  Cancers (Basel)       Date:  2017-12-16       Impact factor: 6.639

6.  HCMV-encoded miR-UL112-3p promotes glioblastoma progression via tumour suppressor candidate 3.

Authors:  Qing Liang; Kejia Wang; Bin Wang; Qiliang Cai
Journal:  Sci Rep       Date:  2017-03-17       Impact factor: 4.379

7.  Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma.

Authors:  Xu-Ren Sheng; Song-Ge Xing; Run-Dong Wang; Kang Chen; Wei-Dong Jia
Journal:  Onco Targets Ther       Date:  2018-02-21       Impact factor: 4.147

8.  miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC.

Authors:  Young-Jun Jeon; Taewan Kim; Dongju Park; Gerard J Nuovo; Siyeon Rhee; Pooja Joshi; Bum-Kyu Lee; Johan Jeong; Sung-Suk Suh; Jeff E Grotzke; Sung-Hak Kim; Jieun Song; Hosung Sim; Yonghwan Kim; Yong Peng; Youngtae Jeong; Michela Garofalo; Nicola Zanesi; Jonghwan Kim; Guang Liang; Ichiro Nakano; Peter Cresswell; Patrick Nana-Sinkam; Ri Cui; Carlo M Croce
Journal:  Nat Commun       Date:  2018-11-30       Impact factor: 14.919

9.  Capture at the single cell level of metabolic modules distinguishing aggressive and indolent glioblastoma cells.

Authors:  Mirca S Saurty-Seerunghen; Léa Bellenger; Elias A El-Habr; Virgile Delaunay; Delphine Garnier; Hervé Chneiweiss; Christophe Antoniewski; Ghislaine Morvan-Dubois; Marie-Pierre Junier
Journal:  Acta Neuropathol Commun       Date:  2019-10-16       Impact factor: 7.801

10.  MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma.

Authors:  Zhen-Xiu Cheng; Wen-Bo Yin; Zhong-Yu Wang
Journal:  Int J Mol Med       Date:  2017-09-07       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.